MaxCyte (MXCT) presentation at ShareSoc July 2018

from PIWORLD Investor Podcasts · host piworld

Driving the next generation of cell-based medicines By Doug Doerfler – Founder, President & CEO Introduction – 00:23 Background and what MaxCyte does - 02:41 Business model – 04:11 CARMA platform, CAR therapy in oncology - 09:07 Cell therapy programmes – business model – 16:12 Revenue potential across multiple applications – 19:15 Expected news flow - 21:36 Summary & outlook – 22:18 2017 financial highlights - 22:50 Q&A - 23:45

Episode metadata supplied by the publisher feed · Published Jul 19, 2018

Embed this episode

Attribution link and audio player

What this episode covers

Driving the next generation of cell-based medicinesBy Doug Doerfler – Founder, President & CEO Introduction – 00:23Background and what MaxCyte does - 02:41Business model – 04:11CARMA platform, CAR therapy in oncology - 09:07Cell therapy programmes – business model – 16:12Revenue potential across multiple applications – 19:15Expected news flow - 21:36Summary & outlook – 22:182017 financial highlights - 22:50Q&A - 23:45

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

MaxCyte (MXCT) presentation at ShareSoc July 2018

0:00 30:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of PIWORLD Investor Podcasts?

This episode is 30 minutes long.

When was this PIWORLD Investor Podcasts episode published?

This episode was published on July 19, 2018.

Can I download this PIWORLD Investor Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!